CummingsSRMartinJSMcClungMR. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765.
2.
OkadaNKawazoeKTeraokaK. Identification of the risk factors associated with hypocalcemia induced by denosumab. Biol Pharm Bull. 2013;36:1622-1626.
3.
McCormickBBDavisJBurnsKD. Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis. 2012;60:626-628.
4.
UngprasertPCheungpasitpornWSrivaliNKittanamongkolchaiWBischofEF. Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am J Emerg Med. 2013;31:756.e751-752.
5.
ShafqatHAlquadanKFOlszewskiAJ. Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome. Osteoporos Int. 2014;25:1187-1190.
6.
McLachlanJMMarxGMBridgmanM. Severe symptomatic hypocalcaemia following a single dose of denosumab. Med J Aust. 2013;199:242-243.
7.
BlockGABoneHGFangLLeeEPadhiD. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27:1471-1479.
8.
JamalSALjunggrenOStehman-BreenC. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26:1829-1835.
9.
ChenCLChenNCHsuCY. An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab. 2014;99:2426-2432.
10.
FarinolaNKanjanapanY. Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure. Int Med J. 2013;43:1243-1246.
